About Beta-1,4-galactosyltransferase 5
Beta-1,4-galactosyltransferase 5 (B4GALT5) is a protein
from Homo sapiens identified by UniProt accession
O43286, 388 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Beta-1,4-galactosyltransferase 5 |
| UniProt accession | O43286 |
| Gene | B4GALT5 |
| Organism | Homo sapiens |
| Length | 388 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (64)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- lysosomal storage disease · score 0.37
- FEV/FVC ratio · score 0.27
- brain measurement · score 0.27
- diastolic blood pressure · score 0.25
- low density lipoprotein cholesterol measurement · score 0.20
- hepatocellular carcinoma · score 0.09
- drug use measurement · score 0.07
- major depressive disorder · score 0.06
- obsessive-compulsive disorder · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43286-F1 | alphafold | PREDICTED | 87.67 | — |
Amino-acid sequence (388 residues)
MRARRGLLRL PRRSLLAALF FFSLSSSLLY FVYVAPGIVN TYLFMMQAQG ILIRDNVRTI GAQVYEQVLR SAYAKRNSSV NDSDYPLDLN HSETFLQTTT FLPEDFTYFA NHTCPERLPS MKGPIDINMS EIGMDYIHEL FSKDPTIKLG GHWKPSDCMP RWKVAILIPF RNRHEHLPVL FRHLLPMLQR QRLQFAFYVV EQVGTQPFNR AMLFNVGFQE AMKDLDWDCL IFHDVDHIPE SDRNYYGCGQ MPRHFATKLD KYMYLLPYTE FFGGVSGLTV EQFRKINGFP NAFWGWGGED DDLWNRVQNA GYSVSRPEGD TGKYKSIPHH HRGEVQFLGR YALLRKSKER QGLDGLNNLN YFANITYDAL YKNITVNLTP ELAQVNEY
Explore Beta-1,4-galactosyltransferase 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets